Legal & General Group
LXEO icon

Legal & General Group’s Lexeo Therapeutics LXEO Stock Holding History

Legal & General Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32K Buy
6,882
+1,251
+22% +$6.77K ﹤0.01% 2925
2026
Q1 		$32.3K Hold
5,631
– – ﹤0.01% 2807
2025
Q4 		$55.9K Buy
5,631
+3,599
+177% +$32.8K ﹤0.01% 2708
2025
Q3 		$13.5K Hold
2,032
– – ﹤0.01% 3204
2025
Q2 		$8.17K Sell
2,032
-495
-20% -$1.63K ﹤0.01% 3336
2025
Q1 		$8.77K Hold
2,527
– – ﹤0.01% 3202
2024
Q4 		$16.6K Hold
2,527
– – ﹤0.01% 3092
2024
Q3 		$22.8K Buy
2,527
+1,517
+150% +$18.1K ﹤0.01% 3001
2024
Q2 		$16.2K Buy
1,010
+147
+17% +$2.13K ﹤0.01% 3113
2024
Q1 		$13.5K Sell
863
-14,137
-94% -$221K ﹤0.01% 3128
2023
Q4 		$202K Buy
+15,000
New +$186K ﹤0.01% 2695

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Legal & General Group's LXEO Position: Q2 2026 in Review

Legal & General Group increased its Lexeo Therapeutics (LXEO) stake by 22% in Q2 2026, buying an estimated $6.77K and bringing the position to 6,882 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #2925.

Legal & General Group first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $202K in Q4 2023. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Legal & General Group held 6,882 shares of Lexeo Therapeutics worth $32K as of Q2 2026.
  • Legal & General Group bought 1,251 Lexeo Therapeutics shares in Q2 2026, an estimated $6.77K.
  • Lexeo Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2925 holding.
  • Legal & General Group first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Legal & General Group's Lexeo Therapeutics position peaked at $202K in Q4 2023.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.